億帆醫藥(002019.SZ):子公司注射用頭孢呋辛鈉通過仿製藥質量和療效一致性評價
格隆匯2月14日丨億帆醫藥(002019.SZ)公佈,公司控股子公司億帆優勝美特醫藥科技有限公司(“億帆優勝美特”)於近日收到股東及藥品受託生產企業浙江巨泰藥業有限公司(“巨泰藥業”)的通知,億帆優勝美特擁有全部權益的在研產品注射用頭孢呋辛鈉,經國家藥品審評中心審查,通過仿製藥質量和療效一致性評價。
注射用頭孢呋辛鈉為第二代頭孢菌素類抗生素,主要用於敏感菌所致的感染,包括呼吸道感染、耳鼻喉感染、泌尿道感染、皮膚及軟組織感染、敗血症、腦膜炎、淋病、骨及關節感染、產褥期和婦科感染等。根據米內網數據顯示,國內注射用頭孢呋辛鈉2019年、2020年銷售額分別為52.27億元、43.75億元。
截止報吿披露日,該產品已投入研發費用約2224.98萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.